Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma

Critical Reviews in Oncology/Hematology

Volumn 41, Issue 3, 2002, Pages 327-334

  Van Herpen, C M L ^a   De Mulder, P H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Interferon ; Interleukin 2; Metastatic renal cell carcinoma; Prognosis

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FLUOROURACIL; INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL RATE; TOXICITY; TREATMENT OUTCOME; KIDNEY TUMOR; METHODOLOGY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 0036009005     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00173-1     Document Type: Article

References (80)

1. Cancer of the kidney and ureter
2. Renal cell carcinoma
3. Cytoreductive nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group Trial 8949
4. Tumor nephrectomy plus interferon α is superior to interferon α alone in metastatic renal cell carcinoma
5. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
6. Interferon gamma-1β compared with placebo in metastatic renal-cell carcinoma
7. Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: An institutional review
8. Resection of metastatic renal cell carcinoma
9. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha
10. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma
11. Virus interference. 1. The interferons
12. Cytokines
13. Immunotherapy of metastatic renal cell cancer
14. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma
15. Treatment of renal cell carcinoma with daily low-dose alpha-interferon
16. A phase I trial of intermittent high dose alpha interferon and dexamethasone in metastatic renal cell carcinoma
17. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients
18. A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: The American Cancer Society collaborative trial
19. Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials
20. Phase II study of interferon alpha in metastatic renal-cell carcinoma: A progress report
21. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma
22. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma
23. Long-term interferon treatment in metastatic renal cell carcinoma
24. Recombinant human interleukin-2, recombinant human interferon-alfa-2a, or both in metastatic renal-cell carcinoma
25. Interferon in renal cell carcinoma. The UCLA experience
26. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
27. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
28. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy
29. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
30. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report
31. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
32. The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2
33. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis
34. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
35. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial
36. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
37. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma
38. Renal dysfunction associated with the administration of high- dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma
39. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma
40. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma
41. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma
42. Subcutaneous administration of interleukin 2 and interferon- alpha-2b in advanced renal cell carcinoma: A confirmatory study
43. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma
44. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma
45. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial
46. Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?
47. Chemotherapy with FUDR in the management of metastatic renal cell carcinoma
48. Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma
49. Combined chemo-immuno-hormonotherapy of advanced renal cell carcinoma
50. Treatment of metastatic renal cell carcinoma with constant rate floxuridine infusion pins recombinant alpha 2b interferon
51. Ifosfamide, vindesine and recombinant alpha-interferon combination chemotherapy for metastatic renal cell carcinoma
52. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer
53. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer
54. Interleukin 2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
55. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil
56. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: Clinical data and laboratory evidence of protease activation
57. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A cytokine working group study
58. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study
59. Interleukin-2 (IL-2) with interferon-alpha (IFN-a) and 5-fluorouracil (5-FU) in patients with metastatic renal cell cancer
60. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
61. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alpha with or without fluorouracil
62. Outpatient treatment with subcutaneous interleukin-2 and interferon alpha administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study
63. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial
64. Chemoimmunotherapy with interleukin-2, interferon-alfa-2b and 5-fluorouracil in outpatients with advanced renal cell carcinoma
65. Results of a randomized clinical trial comparing sc interleukin-2, sc alpha-2a-interferon, and iv bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients
66. Phase III trial of interferon-alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
67. Treatment of advanced renal cell carcinoma with a combination of human lymphoblastoid interferon alpha and cimetidine
68. Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study
69. Sustained oral indomethacin and ranitidine with intermittent continuous infusion interleukin-2 in advanced renal cell carcinoma
70. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma
71. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma
72. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma
73. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
74. Granulocyte-macrophage-colony stimulating factor in metastatic renal cell carcinoma: A phase II trial
75. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
76. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
77. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
78. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma
79. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2
80. Interferon-alpha and survival in renal cell cancer